Salivary Oxytocin as a Marker in Psychedelic Therapy for Depression
Studies whether saliva oxytocin levels during psychedelic therapy relate to depression treatment response.
Plain-language title generated from the registry record
Registry title: Salivary Oxytocin as a Biomarker of Psychedelic Treatment
Key facts
- Where
- Geneva, SwitzerlandSee the site
Where in Switzerland
- Geneva University HospitalsGeneva, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Geneva, Switzerland
- Trial code
- NCT07345858
- Record updated
- 16 January 2026
- Original description
This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.Read full original descriptionShow less
Salivary Oxytocin as a Biomarker of Psychedelic Assisted Psychotherapy in Patients With Major Depressive Disorder
This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.
Inclusion: Age >=18 years-old; MDD defined by DSM-V criteria, and resistant to treatment; Ongoing classical psychotherapeutic treatment; Agreement to discontinue necessary psychotropic medications (some classes of anti-depressants are allowed with no need to taper off).
Exclusion: Psychotic or bipolar disorder; Severe cardiovascular, hepatic or neurological (affecting the central nervous system) disorders; High suicidal risk; Pregnancy or breastfeeding.